These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 16951201)

  • 1. Farnesyltransferase inhibitors reverse taxane resistance.
    Marcus AI; O'Brate AM; Buey RM; Zhou J; Thomas S; Khuri FR; Andreu JM; Díaz F; Giannakakou P
    Cancer Res; 2006 Sep; 66(17):8838-46. PubMed ID: 16951201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
    Marcus AI; Zhou J; O'Brate A; Hamel E; Wong J; Nivens M; El-Naggar A; Yao TP; Khuri FR; Giannakakou P
    Cancer Res; 2005 May; 65(9):3883-93. PubMed ID: 15867388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
    Kim ES; Kies MS; Fossella FV; Glisson BS; Zaknoen S; Statkevich P; Munden RF; Summey C; Pisters KM; Papadimitrakopoulou V; Tighiouart M; Rogatko A; Khuri FR
    Cancer; 2005 Aug; 104(3):561-9. PubMed ID: 16028213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
    Taraboletti G; Micheletti G; Rieppi M; Poli M; Turatto M; Rossi C; Borsotti P; Roccabianca P; Scanziani E; Nicoletti MI; Bombardelli E; Morazzoni P; Riva A; Giavazzi R
    Clin Cancer Res; 2002 Apr; 8(4):1182-8. PubMed ID: 11948131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies.
    Dumontet C; Jordan MA; Lee FF
    Mol Cancer Ther; 2009 Jan; 8(1):17-25. PubMed ID: 19139109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors.
    Ferlini C; Distefano M; Pignatelli F; Lin S; Riva A; Bombardelli E; Mancuso S; Ojima I; Scambia G
    Br J Cancer; 2000 Dec; 83(12):1762-8. PubMed ID: 11104578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taxanes with high potency inducing tubulin assembly overcome tumoural cell resistances.
    Matesanz R; Trigili C; Rodríguez-Salarichs J; Zanardi I; Pera B; Nogales A; Fang WS; Jímenez-Barbero J; Canales A; Barasoain I; Ojima I; Díaz JF
    Bioorg Med Chem; 2014 Sep; 22(18):5078-90. PubMed ID: 25047938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tubulin interacting agents: novel taxanes and epothilones.
    Agrawal NR; Ganapathi R; Mekhail T
    Curr Oncol Rep; 2003 Mar; 5(2):89-98. PubMed ID: 12583825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma.
    Alberti C
    Eur Rev Med Pharmacol Sci; 2013 Jun; 17(12):1658-64. PubMed ID: 23832735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taxane refractory prostate cancer.
    Mathew P; Dipaola R
    J Urol; 2007 Sep; 178(3 Pt 2):S36-41. PubMed ID: 17644120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.
    Tan MH; De S; Bebek G; Orloff MS; Wesolowski R; Downs-Kelly E; Budd GT; Stark GR; Eng C
    Breast Cancer Res Treat; 2012 Feb; 131(3):849-58. PubMed ID: 21479552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells.
    Giannakakou P; Gussio R; Nogales E; Downing KH; Zaharevitz D; Bollbuck B; Poy G; Sackett D; Nicolaou KC; Fojo T
    Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2904-9. PubMed ID: 10688884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer.
    Cassinelli G; Lanzi C; Supino R; Pratesi G; Zuco V; Laccabue D; Cuccuru G; Bombardelli E; Zunino F
    Clin Cancer Res; 2002 Aug; 8(8):2647-54. PubMed ID: 12171897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resistant prostate cancer cells.
    Fujita Y; Kojima T; Kawakami K; Mizutani K; Kato T; Deguchi T; Ito M
    Prostate; 2015 Oct; 75(14):1568-78. PubMed ID: 26074357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
    Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the new generation taxane anticancer agents.
    Geney R; Chen J; Ojima I
    Med Chem; 2005 Mar; 1(2):125-39. PubMed ID: 16787308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between the structures of taxane derivatives and their microtubule polymerization activity.
    Hidaka M; Koga T; Kiyota H; Horiguchi T; Shi QW; Hirose K; Uchida T
    Biosci Biotechnol Biochem; 2012; 76(2):349-52. PubMed ID: 22313785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance.
    Ferlini C; Raspaglio G; Mozzetti S; Cicchillitti L; Filippetti F; Gallo D; Fattorusso C; Campiani G; Scambia G
    Cancer Res; 2005 Mar; 65(6):2397-405. PubMed ID: 15781655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.